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Table 1
Immunization schedule, treatment, and viral challenge
Animal Immunizationa Vaccineb CD8 depletionc Challenged Referencee
K863 4DNA/1Pr DV2F OKT8F SHIVSF162P4
I708 4DNA/1Pr DV2F OKT8F SHIVSF162P4
N472 4DNA/1Pr SF162C OKT8F SHIVSF162P4
P655 4DNA/1Pr SF162C OKT8F SHIVSF162P4
M844 OKT3 SHIVSF162P4
C640 OKT3 SHIVSF162P4
J408 4DNA/2Pr 5V2C OKT8F SHIVSF162P4 Cherpelis et al.
H445 4DNA/2Pr 5V2C OKT8F SHIVSF162P4 Cherpelis et al.
AT54 SHIVSF162P4 Cherpelis et al.
A141 SHIVSF162P4 Cherpelis et al.
a The animals were immunized (both intramuscularly and intradermally) 3 times with a DNAvector expressing the HIV Env. A fourth DNA immunization was
administered 10 months later and at the same time the animals were immunized with the purified soluble trimeric HIV envelope recombinant protein. Animals
J408 and H445 received a second immunization with recombinant protein (in the absence of DNA immunization) 2 months following the first protein
administration.
b The vaccine was the gp140 envelope form derived from the SF162DV2 virus (DV2) or derived from the SF162 virus (SF162). C: The gp120–gp41 cleavage
site is present on the immunogen during the DNA phase of immunization. F: The gp120–gp41 cleavage site is absent on the immunogen during the DNA
phase of immunization.
c Transient depletion of CD8+ cells from the immunized animals was achieved by administering the anti-CD8 MAb OKT8F. Two control animals, M844 and
C640, received OKT3, a nonspecific isotype control MAb.
d The animals were challenged intravenously 7 weeks following the last protein-boost immunization.
e We previously reported on the immunization and challenge as well on the viral load data during the acute phase of infection of these four animals and are now
reporting on the virological and immunological analyses performed during chronic infection.
